Clinical trial
Study of XL820 Given Orally Daily to Subjects With Solid Tumors
NCT00350831 · Exelixis, Industry · Completed
Key facts
| NCT number | NCT00350831 |
|---|---|
| Title | Study of XL820 Given Orally Daily to Subjects With Solid Tumors |
| Official title | A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the KIT Inhibitor XL820 Administered Orally Daily to Subjects With Solid Tumors |
| Lead sponsor | Exelixis, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | XL820 |
| Enrollment | 30 |
| Start date | Jul 1, 2006 |
| First posted | Jul 11, 2006 |
| Last update posted | Aug 18, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: